Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1996 Jul;49(7):552–555. doi: 10.1136/jcp.49.7.552

Hepatitis virus infection and liver disease in injecting drug users who died suddenly.

E A McCruden 1, K J Hillan 1, I C McKay 1, M T Cassidy 1, J C Clark 1
PMCID: PMC500568  PMID: 8813952

Abstract

AIM: To determine the extent of liver damage resulting from infection with hepatitis B, C and D viruses (HBV, HCV and HDV) in intravenous drug users (IDUs). METHODS: Liver sections taken at necropsy performed to investigate the cause of sudden death in 48 IDUs were scored for necroinflammatory activity and fibrosis. Evidence of infection was by detection of viral antibodies in serum, hepatitis B surface antigen (HBsAg) and HCV RNA by reverse transcription-polymerase chain reaction (RT-PCR). RESULTS: Evidence of HCV infection was present in 43 (90%) of 48 serum samples. Six (12%) HBsAg positive serum samples had markers indicative of chronic HBsAg carriage, including three with antibody directed against HDV. Evidence of past HBV infection was found in 27 (69%) of 39 HBsAg negative serum samples. HIV was detected in one (2%) of 48 samples. In five (10%) of 48 samples there was no evidence of current or past infection with HCV, HBV or HIV. All 43 liver sections from HCV positive IDUs scored > or = 1 for necroinflammatory activity, whereas three IDUs without HCV scored 0. Scores for stage of fibrosis were > or = 1 in 15 (35%) of 43 and zero of five IDUs, respectively. Fibrosis scores of > or = 3 were seen only in three IDUs positive for HBV, HDV and HCV. CONCLUSION: Inflammatory activity in the liver is present in a high proportion of IDUs in Glasgow and is strongly associated with HCV infection. Severe chronic liver damage was limited to HBsAg carriers superinfected with HDV and HCV.

Full text

PDF
552

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Choo Q. L., Richman K. H., Han J. H., Berger K., Lee C., Dong C., Gallegos C., Coit D., Medina-Selby R., Barr P. J. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2451–2455. doi: 10.1073/pnas.88.6.2451. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Covell R., Follett E., Coote I., Bloor M., Finlay A., Frischer M., Goldberg D., Green S., Haw S., McKeganey N. HIV testing among injecting drug users in Glasgow. J Infect. 1993 Jan;26(1):27–31. doi: 10.1016/0163-4453(93)96712-y. [DOI] [PubMed] [Google Scholar]
  3. Donahue J. G., Nelson K. E., Muñoz A., Vlahov D., Rennie L. L., Taylor E. L., Saah A. J., Cohn S., Odaka N. J., Farzadegan H. Antibody to hepatitis C virus among cardiac surgery patients, homosexual men, and intravenous drug users in Baltimore, Maryland. Am J Epidemiol. 1991 Nov 15;134(10):1206–1211. doi: 10.1093/oxfordjournals.aje.a116023. [DOI] [PubMed] [Google Scholar]
  4. Houghton M., Weiner A., Han J., Kuo G., Choo Q. L. Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease. Hepatology. 1991 Aug;14(2):381–388. [PubMed] [Google Scholar]
  5. Kelen G. D., Green G. B., Purcell R. H., Chan D. W., Qaqish B. F., Sivertson K. T., Quinn T. C. Hepatitis B and hepatitis C in emergency department patients. N Engl J Med. 1992 May 21;326(21):1399–1404. doi: 10.1056/NEJM199205213262105. [DOI] [PubMed] [Google Scholar]
  6. Kiyosawa K., Tanaka E., Sodeyama T., Furuta S. Natural history of hepatitis C. Intervirology. 1994;37(2):101–107. doi: 10.1159/000150363. [DOI] [PubMed] [Google Scholar]
  7. McCruden E. A., Follett E. A. Hepatitis delta virus infections in intravenous drug abusers with hepatitis B in the west of Scotland. J Med Virol. 1989 Sep;29(1):59–62. doi: 10.1002/jmv.1890290111. [DOI] [PubMed] [Google Scholar]
  8. McCruden E. A., Welch S., Batchelor B., Allison M. C., Dow B., Follett E. A., Mills P. R., Briggs J. D. Hepatitis C virus infection detected by antibody tests and the polymerase chain reaction as a cause of liver dysfunction in renal transplant recipients. J Med Virol. 1994 Feb;42(2):158–163. doi: 10.1002/jmv.1890420211. [DOI] [PubMed] [Google Scholar]
  9. Quaranta J. F., Delaney S. R., Alleman S., Cassuto J. P., Dellamonica P., Allain J. P. Prevalence of antibody to hepatitis C virus (HCV) in HIV-1-infected patients (nice SEROCO cohort). J Med Virol. 1994 Jan;42(1):29–32. doi: 10.1002/jmv.1890420106. [DOI] [PubMed] [Google Scholar]
  10. Scheuer P. J. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol. 1991 Nov;13(3):372–374. doi: 10.1016/0168-8278(91)90084-o. [DOI] [PubMed] [Google Scholar]
  11. Seeff L. B., Buskell-Bales Z., Wright E. C., Durako S. J., Alter H. J., Iber F. L., Hollinger F. B., Gitnick G., Knodell R. G., Perrillo R. P. Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med. 1992 Dec 31;327(27):1906–1911. doi: 10.1056/NEJM199212313272703. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES